» Articles » PMID: 31303501

Paricalcitol Accelerates BACE1 Lysosomal Degradation and Inhibits Calpain-1 Dependent Neuronal Loss in APP/PS1 Transgenic Mice

Overview
Journal EBioMedicine
Date 2019 Jul 16
PMID 31303501
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Recent studies have revealed that vitamin D deficiency may increase the risk of Alzheimer's disease, and vitamin D supplementation may be effective strategy to ameliorate the neurodegenerative process in Alzheimer's disease patients. Paricalcitol (PAL), a low-calcemic vitamin D receptor agonist, is clinically used to treat secondary hyperparathyroidism. However, the potential application of PAL for treating neurodegenerative disorders remains unexplored.

Methods: The APP/PS1 mice were intraperitoneally injected with PAL or vehicle every other day for 15 weeks. The β-amyloid (Aβ) production was confirmed using immunostaining and enzyme linked immunosorbent assay. The underlying mechanism was verified by western blot and immunostaining in vivo and in vitro.

Findings: Long-term PAL treatment clearly reduced β-amyloid (Aβ) generation and neuronal loss in APP/PS1 transgenic mouse brains. PAL stimulated the expression of low-density lipoprotein receptor-related protein 1 (LRP1) possibly through inhibiting sterol regulatory element binding protein-2 (SREBP2); PAL also promoted LRP1-mediated β-site APP cleavage enzyme 1 (BACE1) transport to late endosomes, thus increasing the lysosomal degradation of BACE1. Furthermore, PAL diminished 8-hydroxyguanosine (8-OHdG) generation in neuronal mitochondria via enhancing base excision repair (BER), resulting in the attenuation of calpain-1-mediated neuronal loss.

Interpretation: The present data demonstrate that PAL can reduce Aβ generation through accelerating BACE1 lysosomal degradation and can inhibit neuronal loss through suppressing mitochondrial 8-OHdG generation. Hence, PAL might be a promising agent for treating Alzheimer's disease. FUND: This study was financially supported by the Natural Science Foundation of China (U1608282).

Citing Articles

Identification of AS1842856 as a novel small-molecule GSK3α/β inhibitor against Tauopathy by accelerating GSK3α/β exocytosis.

He D, Zhang X, Su J, Zhang Q, Zhao L, Wu T Aging Cell. 2024; 24(1):e14336.

PMID: 39287420 PMC: 11709109. DOI: 10.1111/acel.14336.


The Role of Endophilin A1 in Lipopolysaccharide-Induced Parkinson's Disease Model Mice.

Han J, Liu M, Ling Y, Ren Y, Qiu Y, Liu Y J Parkinsons Dis. 2023; 13(5):743-756.

PMID: 37334616 PMC: 10473136. DOI: 10.3233/JPD-225098.


Vitamin D and Its Analogues: From Differences in Molecular Mechanisms to Potential Benefits of Adapted Use in the Treatment of Alzheimer's Disease.

Thiel A, Hermanns C, Lauer A, Reichrath J, Erhardt T, Hartmann T Nutrients. 2023; 15(7).

PMID: 37049524 PMC: 10096957. DOI: 10.3390/nu15071684.


The Vitamin D Receptor as a Potential Target for the Treatment of Age-Related Neurodegenerative Diseases Such as Alzheimer's and Parkinson's Diseases: A Narrative Review.

Lason W, Jantas D, Leskiewicz M, Regulska M, Basta-Kaim A Cells. 2023; 12(4).

PMID: 36831327 PMC: 9954016. DOI: 10.3390/cells12040660.


Energy Crisis Links to Autophagy and Ferroptosis in Alzheimer's Disease: Current Evidence and Future Avenues.

He D, Fan Y, Wang Z Curr Neuropharmacol. 2022; 21(1):67-86.

PMID: 35980072 PMC: 10193753. DOI: 10.2174/1570159X20666220817140737.


References
1.
Brunholz S, Sisodia S, Lorenzo A, Deyts C, Kins S, Morfini G . Axonal transport of APP and the spatial regulation of APP cleavage and function in neuronal cells. Exp Brain Res. 2011; 217(3-4):353-64. PMC: 3670699. DOI: 10.1007/s00221-011-2870-1. View

2.
Dursun E, Gezen-Ak D . Vitamin D receptor is present on the neuronal plasma membrane and is co-localized with amyloid precursor protein, ADAM10 or Nicastrin. PLoS One. 2017; 12(11):e0188605. PMC: 5703467. DOI: 10.1371/journal.pone.0188605. View

3.
Tanokashira D, Motoki K, Minegishi S, Hosaka A, Mamada N, Tamaoka A . LRP1 Downregulates the Alzheimer's β-Secretase BACE1 by Modulating Its Intraneuronal Trafficking. eNeuro. 2015; 2(2). PMC: 4596091. DOI: 10.1523/ENEURO.0006-15.2015. View

4.
Bouillon R . Genetic and environmental determinants of vitamin D status. Lancet. 2010; 376(9736):148-9. DOI: 10.1016/S0140-6736(10)60635-6. View

5.
Li S, He Y, Lin S, Hao L, Ye Y, Lv L . Increase of circulating cholesterol in vitamin D deficiency is linked to reduced vitamin D receptor activity via the Insig-2/SREBP-2 pathway. Mol Nutr Food Res. 2015; 60(4):798-809. DOI: 10.1002/mnfr.201500425. View